These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37391174)

  • 41. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
    Farhat LC; Behling E; Landeros-Weisenberger A; Levine JLS; Macul Ferreira de Barros P; Wang Z; Bloch MH
    Lancet Child Adolesc Health; 2023 Feb; 7(2):112-126. PubMed ID: 36528030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
    Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
    J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis.
    Ostacher M; Ng-Mak D; Patel P; Ntais D; Schlueter M; Loebel A
    World J Biol Psychiatry; 2018 Dec; 19(8):586-601. PubMed ID: 28264635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis.
    Siskind D; Gallagher E; Winckel K; Hollingworth S; Kisely S; Firth J; Correll CU; Marteene W
    Schizophr Bull; 2021 Jul; 47(4):948-958. PubMed ID: 33547471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.
    Kishi T; Yoshimura R; Sakuma K; Okuya M; Iwata N
    Neuropsychopharmacol Rep; 2020 Dec; 40(4):417-422. PubMed ID: 32902200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
    Temmingh HS; Williams T; Siegfried N; Stein DJ
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011057. PubMed ID: 29355909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
    Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
    Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
    Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
    L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
    J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.
    Bahji A; Ermacora D; Stephenson C; Hawken ER; Vazquez G
    J Affect Disord; 2020 May; 269():154-184. PubMed ID: 32339131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Likhitsathian S; Suttajit S; Maneeton N; Maneeton B; Oon-Arom A; Suradom C
    Drug Alcohol Depend; 2021 Feb; 219():108467. PubMed ID: 33385693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
    Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
    Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
    Kishi T; Ikuta T; Matsuda Y; Sakuma K; Okuya M; Mishima K; Iwata N
    Mol Psychiatry; 2021 Aug; 26(8):4146-4157. PubMed ID: 33177610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Second-Generation Antipsychotics in Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-analysis.
    Patel RS; Veluri N; Patel J; Patel R; Machado T; Diler R
    J Child Adolesc Psychopharmacol; 2021 Oct; 31(8):521-530. PubMed ID: 34665020
    [No Abstract]   [Full Text] [Related]  

  • 60. Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia.
    Crump CJ; Good ME; Abuelazm H; El-Mallakh RS
    Expert Opin Pharmacother; 2023 Jun; 24(9):1039-1052. PubMed ID: 37102321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.